- Home
- CAG vs ACLX Comparison
CAG vs ACLX Comparison
Compare CAG & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAG | ACLX |
|---|---|---|
| Founded | 1919 | 2015 |
| Country | United States | United States |
| Employees | 26100 | 209 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 6.7B |
| IPO Year | 1994 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CAG | ACLX |
|---|---|---|
| Price | $14.12 | $115.04 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 17 | 15 |
| Target Price | $16.88 | ★ $115.85 |
| AVG Volume (30 Days) | ★ 14.1M | 794.0K |
| Earning Date | 04-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 9.71% | N/A |
| EPS Growth | ★ 233.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,500,000,000.00 | $22,286,000.00 |
| Revenue This Year | N/A | $342.39 |
| Revenue Next Year | N/A | $170.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.04 | $47.86 |
| 52 Week High | $24.80 | $115.13 |
Technical Indicators
Market Signals| Indicator | CAG | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 31.02 | 79.59 |
| Support Level | $14.04 | $63.46 |
| Resistance Level | $19.54 | N/A |
| Average True Range (ATR) | 0.41 | 0.10 |
| MACD | 0.02 | -0.66 |
| Stochastic Oscillator | 4.74 | 76.83 |
Price Performance
Historical ComparisonAbout CAG ConAgra Brands Inc.
Conagra Brands is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, and Wish-Bone. The company primarily sells through the US retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.